Activation of β‑adrenergic receptor promotes cellular proliferation in human glioblastoma

He,Jing‑Jing; Zhang,Wen‑Hua; Liu,Shi‑Ling; Chen,Yi‑Fang; Liao,Chen‑Xi; Shen,Qian‑Qing; Hu,Ping

doi:10.3892/ol.2017.6653

Activation of β‑adrenergic receptor promotes cellular proliferation in human glioblastoma

Authors:
- Jing‑Jing He
- Wen‑Hua Zhang
- Shi‑Ling Liu
- Yi‑Fang Chen
- Chen‑Xi Liao
- Qian‑Qing Shen
- Ping Hu
View Affiliations

Affiliations: Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330001, P.R. China, Institute of Life Science, Nanchang University, Nanchang, Jiangxi 330031, P.R. China
Published online on: July 21, 2017 https://doi.org/10.3892/ol.2017.6653
Pages: 3846-3852

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma multiforme is the most common and aggressive form of primary malignant brain tumor. Previous evidence demonstrates that β‑adrenergic receptors (β‑ARs) are closely associated with the occurrence and development of brain tumors. However, the functional role of β‑ARs in human glioblastoma and the underlying mechanisms are not fully understood. In the present study, by using the MTT assay, western blotting, and the reverse transcription polymerase chain reaction, it was revealed that isoproterenol (ISO), an agonist of β‑ARs, promoted the proliferation of U251 cells but not U87‑MG cells, and that this effect was blocked by the β‑ARs antagonist propranolol. It was also demonstrated that ISO transiently induced extracellular signal‑related kinase 1/2 (ERK1/2) phosphorylation, and that blocking the mitogen-activated protein kinase pathway by U0126 inhibited ERK1/2 phosphorylation and suppressed U251 cell proliferation. In addition, β‑ARs activation increased the expression of matrix metalloproteinase (MMP) family members MMP‑2 and MMP‑9 mRNA through ERK1/2 activation. In conclusion, these data suggest that β‑ARs induce ERK1/2 phosphorylation, which may in turn increase MMPs expression to promote U251 cell proliferation. These results provide additional insight into the specific roles of β‑ARs in glioblastoma.

View Figures

View References

1	Dolecek TA, Propp JM, Stroup NE and Kruchko C: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 14:(Suppl 5). v1–v49. 2012. View Article : Google Scholar : PubMed/NCBI
2	Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
3	Stupp R and Roila F: ESMO Guidelines Working Group: Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 20:(Suppl 4). S126–S128. 2009. View Article : Google Scholar
4	Nagaraja AS, Armaiz-Pena GN, Lutgendorf SK and Sood AK: Why stress is BAD for cancer patients. J Clin Invest. 123:558–560. 2013.PubMed/NCBI
5	Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, et al: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 12:939–944. 2006. View Article : Google Scholar : PubMed/NCBI
6	Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A, Register T, Cline JM, D'Agostino R Jr, Danial N, et al: Behavioral stress accelerates prostate cancer development in mice. J Clin Invest. 123:874–886. 2013.PubMed/NCBI
7	Timmermans W, Xiong H, Hoogenraad CC and Krugers HJ: Stress and excitatory synapses: From health to disease. Neuroscience. 248:626–636. 2013. View Article : Google Scholar : PubMed/NCBI
8	de Kloet ER, Joëls M and Holsboer F: Stress and the brain: From adaptation to disease. Nat Rev Neurosci. 6:463–475. 2005. View Article : Google Scholar : PubMed/NCBI
9	Fitzgerald PJ: Is norepinephrine an etiological factor in some types of cancer? Int J Cancer. 124:257–263. 2009. View Article : Google Scholar : PubMed/NCBI
10	Woo AY and Xiao RP: β-adrenergic receptor subtype signaling in heart: From bench to bedside. Acta Pharmacol Sin. 33:335–341. 2012. View Article : Google Scholar : PubMed/NCBI
11	Schuller HM and Al-Wadei HA: Neurotransmitter receptors as central regulators of pancreatic cancer. Future Oncol. 6:221–228. 2010. View Article : Google Scholar : PubMed/NCBI
12	Cohen S, Janicki-Deverts D and Miller GE: Psychological stress and disease. JAMA. 298:1685–1687. 2007. View Article : Google Scholar : PubMed/NCBI
13	Schuller HM: Beta-adrenergic signaling, a novel target for cancer therapy? Oncotarget. 1:466–469. 2010. View Article : Google Scholar : PubMed/NCBI
14	Braadland PR, Ramberg H, Grytli HH and Taskén KA: β-adrenergic receptor signaling in prostate cancer. Front Oncol. 4:3752015. View Article : Google Scholar : PubMed/NCBI
15	Al-Wadei HA, Al-Wadei MH and Schuller HM: Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer Drugs. 20:477–482. 2009. View Article : Google Scholar : PubMed/NCBI
16	Askari MD, Tsao MS and Schuller HM: The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors. J Cancer Res Clin Oncol. 131:639–648. 2005. View Article : Google Scholar : PubMed/NCBI
17	Weddle DL, Tithoff P, Williams M and Schuller HM: Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis. 22:473–479. 2001. View Article : Google Scholar : PubMed/NCBI
18	Toll L, Jimenez L, Waleh N, Jozwiak K, Woo AY, Xiao RP, Bernier M and Wainer IW: {Beta}2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells. J Pharmacol Exp Ther. 336:524–532. 2011. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Hu P, He J, Liu S, Wang M, Pan B and Zhang W: β2-adrenergic receptor activation promotes the proliferation of A549 lung cancer cells via the ERK1/2/CREB pathway. Oncol Rep. 36:1757–1763. 2016.PubMed/NCBI
21	Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290. 2007. View Article : Google Scholar : PubMed/NCBI
22	Dong W, Li H, Zhang Y, Yang H, Guo M, Li L and Liu T: Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer. Acta Biochim Biophys Sin (Shanghai). 43:840–848. 2011. View Article : Google Scholar : PubMed/NCBI
23	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
24	Annabi B, Lachambre MP, Plouffe K, Moumdjian R and Béliveau R: Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res. 60:438–445. 2009. View Article : Google Scholar : PubMed/NCBI
25	Sardi I, Giunti L, Bresci C, Buccoliero AM, Degl'innocenti D, Cardellicchio S, Baroni G, Castiglione F, Ros MD, Fiorini P, et al: Expression of β-adrenergic receptors in pediatric malignant brain tumors. Oncol Lett. 5:221–225. 2013.PubMed/NCBI
26	Prenner L, Sieben A, Zeller K, Weiser D and Häberlein H: Reduction of high-affinity beta2-adrenergic receptor binding by hyperforin and hyperoside on rat C6 glioblastoma cells measured by fluorescence correlation spectroscopy. Biochemistry. 46:5106–5113. 2007. View Article : Google Scholar : PubMed/NCBI
27	Wakshull E, Hertel C, O'Keefe EJ and Perkins JP: Cellular redistribution of beta-adrenergic receptors in a human astrocytoma cell line: A comparison with the epidermal growth factor receptor in murine fibroblasts. J Cell Biochem. 29:127–141. 1985. View Article : Google Scholar : PubMed/NCBI
28	Paul RK, Ramamoorthy A, Scheers J, Wersto RP, Toll L, Jimenez L, Bernier M and Wainer IW: Cannabinoid receptor activation correlates with the proapoptotic action of the β2-adrenergic agonist (R,R')-4-methoxy-1-naphthylfenoterol in HepG2 hepatocarcinoma cells. J Pharmacol Exp Ther. 343:157–166. 2012. View Article : Google Scholar : PubMed/NCBI
29	Evans BA, Sato M, Sarwar M, Hutchinson DS and Summers RJ: Ligand-directed signalling at beta-adrenoceptors. Br J Pharmacol. 159:1022–1038. 2010. View Article : Google Scholar : PubMed/NCBI
30	Yuan A, Li Z, Li X, Yi S, Wang S, Cai Y and Cao H: The mitogenic effectors of isoproterenol in human hepatocellular carcinoma cells. Oncol Rep. 23:151–157. 2010.PubMed/NCBI
31	Pham H, Chen M, Takahashi H, King J, Reber HA, Hines OJ, Pandol S and Eibl G: Apigenin inhibits NNK-induced focal adhesion kinase activation in pancreatic cancer cells. Pancreas. 41:1306–1315. 2012. View Article : Google Scholar : PubMed/NCBI
32	Zhang P, He X, Tan J, Zhou X and Zou L: β-arrestin2 mediates β-2 adrenergic receptor signaling inducing prostate cancer cell progression. Oncol Rep. 26:1471–1477. 2011.PubMed/NCBI
33	Shin VY, Wu WK, Chu KM, Koo MW, Wong HP, Lam EK, Tai EK and Cho CH: Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells. Toxicol Sci. 96:21–29. 2007. View Article : Google Scholar : PubMed/NCBI
34	Coelho M, Moz M, Correia G, Teixeira A, Medeiros R and Ribeiro L: Antiproliferative effects of β-blockers on human colorectal cancer cells. Oncol Rep. 33:2513–2520. 2015.PubMed/NCBI
35	Slotkin TA, Zhang J, Dancel R, Garcia SJ, Willis C and Seidler FJ: Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat. 60:153–166. 2000. View Article : Google Scholar : PubMed/NCBI
36	Carie AE and Sebti SM: A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene. 26:3777–3788. 2007. View Article : Google Scholar : PubMed/NCBI
37	Schuller HM, Al-Wadei HA and Majidi M: GABA B receptor is a novel drug target for pancreatic cancer. Cancer. 112:767–778. 2008. View Article : Google Scholar : PubMed/NCBI
38	Cottingham C, Lu R, Jiao K and Wang Q: Cross-talk from β-adrenergic receptors modulates α2A-adrenergic receptor endocytosis in sympathetic neurons via protein kinase A and spinophilin. J Biol Chem. 288:29193–29205. 2013. View Article : Google Scholar : PubMed/NCBI
39	Hanke S, Nürnberg B, Groll DH and Liebmann C: Cross talk between beta-adrenergic and bradykinin B(2) receptors results in cooperative regulation of cyclic AMP accumulation and mitogen-activated protein kinase activity. Mol Cell Biol. 21:8452–8460. 2001. View Article : Google Scholar : PubMed/NCBI
40	Wrzal PK, Goupil E, Laporte SA, Hébert TE and Zingg HH: Functional interactions between the oxytocin receptor and the β2-adrenergic receptor: Implications for ERK1/2 activation in human myometrial cells. Cell Signal. 24:333–341. 2012. View Article : Google Scholar : PubMed/NCBI
41	Deryugina EI and Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
42	Moreno-Smith M, Lutgendorf SK and Sood AK: Impact of stress on cancer metastasis. Future Oncol. 6:1863–1881. 2010. View Article : Google Scholar : PubMed/NCBI
43	Xiao LJ, Lin P, Lin F, Liu X, Qin W, Zou HF, Guo L, Liu W, Wang SJ and Yu XG: ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol. 40:1714–1724. 2012.PubMed/NCBI